Unitaid has invested more than US$ 45 million into hepatitis C since 2015, driving the development of better and more affordable tools and demonstrating that it is possible to reach – and cure – people in resource-limited settings.
“We set out to improve hepatitis C care through a complementary set of investments. Over the past six years we have helped make essential medicines available, simplify testing and treatment, improve diagnostic tools, bring care closer to the people at-risk, and raise awareness of treatment programmes with affected communities and governments,” said Dr Philippe Duneton, Executive Director of Unitaid.
On World Hepatitis Day, 28 July, Unitaid celebrates this progress, delivered in partnership with Médecins Sans Frontières (MSF), Foundation for Innovative New Diagnostics (FIND) Coalition PLUS, Medicines Patent Pool (MPP) and the World Health Organization (WHO) and looks towards 2030 elimination targets.
